English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 905178      Online Users : 914
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12290


    Title: Discovery of a furanopyrimidine-based epidermal growth factor receptor inhibitor (DBPR112) as a clinical candidate for the treatment of non-small cell lung cancer
    Authors: Lin, SY;Chang Hsu, Y;Peng, YH;Ke, YY;Lin, WH;Sun, HY;Shiao, HY;Kuo, FM;Chen, PY;Lien, TW;Chen, CH;Chu, CY;Wang, SY;Yeh, KC;Chen, CP;Hsu, TA;Wu, SY;Yeh, TK;Chen, CT;Hsieh, HP
    Contributors: Institute of Biotechnology and Pharmaceutical Research
    Abstract: Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, furanopyrimidine 2, which contains a (S)-2-phenylglycinol structure as a key fragment to inhibit EGFR. However, compound 2 showed high clearance and poor oral bioavailability in its pharmacokinetics studies. In this work, we optimized compound 2 by scaffold hopping and exploiting the potent inhibitory activity of various warhead groups to obtain a clinical candidate, 78 (DBPR112), which not only displayed a potent inhibitory activity against EGFRL858R/T790M double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib, against EGFR and HER2 exon 20 insertion mutations. Overall, pharmacokinetic improvement through lead-to-candidate optimization yielded fourfold oral AUC better that afatinib along with F = 41.5%, an encouraging safety profile, and significant antitumor efficacy in in vivo xenograft models. DBPR112 is currently undergoing phase 1 clinical trial in Taiwan.
    Date: 2019-11-27
    Relation: Journal of Medicinal Chemistry. 2019 Nov 27;62(22):10108-10123.
    Link to: http://dx.doi.org/10.1021/acs.jmedchem.9b00722
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0022-2623&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000500420100007
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85075574489
    Appears in Collections:[謝興邦] 期刊論文
    [陳炯東] 期刊論文
    [葉燈光] 期刊論文
    [徐祖安] 期刊論文
    [伍素瑩] 期刊論文
    [林書玉] 期刊論文

    Files in This Item:

    File Description SizeFormat
    NBP2019112001.pdf5444KbAdobe PDF399View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback